View Clinical Trial (Medical Research Study)
A Study of Inhalation of 20,000 EU CCRE and Mucociliary Clearance (MCC) in Otherwise Healthy Individuals Who Are Current Cigarette Smokers - NCT00924768-27599(Clinical Trial 298599)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
Chapel Hill |
|
State:
|
|
NC |
| Zip Code: |
|
27599 |
| Conditions: |
|
Healthy - Cigarette Smoking |
| Purpose: |
|
The purpose of this Phase 1 research study is to identify a dose of inhaled endotoxin that
is safe (does not cause prolonged cough, shortness of breath or other problems), but causes
changes in sputum cell samples that the scientists can measure. The investigators are also
interested in seeing if the exposure to the endotoxin decreases the body's natural ability
to clear mucus from the lungs.
|
| Study summary: |
|
The purpose of this study is to determine the range of neutrophil response (influx of PMNs
to the airways as determined in sputum) after inhalation of CCRE (20,000 EU), shown in
previous studies of healthy, nonsmoking volunteers as well as in a limited number of
otherwise healthy smokers to be well tolerated. This dose induces measurable increases in
neutrophil content of induced sputum that can be employed to screen large populations for
susceptibility to the inflammatory effect of inhaled endotoxin. Limitations of the
understanding of actions of inflammatory stimuli on airway function are likely due to the
fact that functional assessments of dynamic airway response /in vivo/ have generally been
limited to those based on spirometry and examination of airway samples for assessment of
cells and mediator content. Slowing of mucociliary clearance (MCC), a key component of
airway defense, can be induced by inflammation and almost certainly contribute to mucus
plugging and decreased clearance of inhaled irritants. Measures of mucociliary clearance
(MCC), by inhalation of radiolabeled particles to label airway surface liquid, suggest that
clearance of secretions is impaired to a mild degree in smokers and more severely in
patients hospitalized for acute exacerbations. |
| Criteria: |
|
Inclusion Criteria:
- Must be current cigarette smokers
- Must be otherwise healthy
- Must be good sputum producers
Exclusion Criteria:
- Any acute illness any chronic illness which would impact results |
|
|
|
|
|
|
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
October 22, 2010 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|